Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Down 77.6% in June

Bioxytran, Inc. (OTCMKTS:BIXT) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 2,800 shares, a decrease of 77.6% from the May 31st total of 12,500 shares. Based on an average daily trading volume, of 120,500 shares, the short-interest ratio is presently 0.0 days.

Bioxytran Price Performance

Shares of BIXT remained flat at $0.10 during midday trading on Friday. 72,435 shares of the company’s stock traded hands, compared to its average volume of 78,557. The firm has a 50 day simple moving average of $0.12 and a 200 day simple moving average of $0.12. Bioxytran has a twelve month low of $0.07 and a twelve month high of $0.35.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.